X

Drug Profile

ALM 004

Alternative Names: ALM-004

Latest Information Update: 29 Dec 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Almatica Pharma
Class Sleep disorder therapies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preregistration Sleep disorders

Most Recent Events

29 Dec 2022 Phase-II clinical trials in Sleep disorders in USA, prior to December 2022 (Almatica pipeline, December 2022)
29 Dec 2022 Phase-III clinical trials in Sleep disorders in USA, prior to December 2022 (Almatica pipeline, December 2022)
29 Dec 2022 Preregistration for Sleep disorders in USA, prior to December 2022 (Almatica pipeline, December 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com